The Biotech Company of the Year awards recognize achievements including "moving the business from an early stage to a more mature company, signing a transformative deal, taking its first or a major new product towards the market, or raising significant new funds".

CEO Yvonne Lungershausen and Chief Strategy Officer Ben Edwards are attending the awards night and hosting a table for biotech clients in Japan next week.

Avance Clinical, which is backed by global private equity firm The Riverside Company, is in the process of regional and international expansion plans.

Along with Avance Clinical, the finalists for the Best Contract Research Organization APAC are:

- Calyx

- CMIC Group

- EPS

- ICON

- Parexel

- Syneos Health

Avance Clinical's CEO Yvonne Lungershausen said: "Avance Clinical is extremely pleased to be sponsoring these biotech awards. We are the CRO for international biotechs and this collaboration with Informa Pharma Intelligence shows our ongoing support and investment for the biotech industry."

The finalists for Biotech Company of the Year - Private:

- ARTham Therapeutics

- Chordia Therapeutics

- Cuorips

- Heartseed

- Prism BioLab

- Rebirthel

- ReboRNA Biosciences

- TMS

The finalists for Biotech Company of the Year - Public:

- NanoCarrier

- Rakuten Medical (Rakuten Group Inc.'s equity accounted affiliate)

- Sosei Heptares

- Stella Pharma

- StemCell Institute

"In addition, we are extremely honored to be selected as a finalist for the prestigious award Best Contract Research Organization in APAC. It is a credit to our customer-focused team for delivering world-leading CRO services for biotechs which has been recognized by the Informa Pharma Intelligence award judges. Avance Clinical has a global reputation for agile clinical solutions to support accelerated clinical development for our international biotech clients. We are very proud of our growth and success in recent years."

According to Informa Pharma Intelligence, this Award is to recognize CROs that provide full or specialist services to their clients and which have an office in either in Japan or the Asia region including Australia. Judging considers the quality of services and relationships built with clients and pays particular attention to the innovative patient recruitment strategies the CRO has brought to the table. The award is based on achievements in the 2021 calendar year.

Core areas judged include:

- The particular capabilities and strengths the CRO offers

- How the company has delivered results that exceed sponsor expectations

- Innovations in patient recruitment strategy has the CRO brought to its partner

- How it has improved its performance, for example, in its quality of data, timelines and transparency

- The steps the company is taking towards streamlining data collection and reporting

To find out more please visit: https://pharmaintelligence.informa.com/events/awards/japan-awards-2022/shortlist-2022

Avance Clinical is the Australian-owned CRO that provides global regulatory standard clinical research services across all phases to the local and international biopharma industry.

Click here to continue